Patents Assigned to Myovant Sciences GmbH
-
Patent number: 11638740Abstract: Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyperstimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-N?-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 23, 2021Date of Patent: May 2, 2023Assignee: Myovant Sciences GmbHInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, Laura Ann Williams
-
Patent number: 11607440Abstract: Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyperstimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-N?-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 23, 2021Date of Patent: March 21, 2023Assignee: Myovant Sciences GmbHInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, Laura Ann Williams
-
Patent number: 11583526Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 20, 2020Date of Patent: February 21, 2023Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
-
Patent number: 11033551Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: March 29, 2019Date of Patent: June 15, 2021Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11013780Abstract: Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyperstimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-N?-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 29, 2019Date of Patent: May 25, 2021Assignee: Myovant Sciences GmbHInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, Laura Ann Williams
-
Patent number: 10786501Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 6, 2019Date of Patent: September 29, 2020Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
-
Patent number: 10449191Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 29, 2019Date of Patent: October 22, 2019Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.